Reveragen Biopharma Inc is categorized under Noncommercial Biotechnical Research in Rockville, MD and active since 2008.
Reveragen Biopharma Inc was established in 2008, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Noncommercial Biotechnical Research business, which does work in the B2B market, and is classified as a Noncommercial Biotechnical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Eric Hoffman at the company’s single location by writing to 9700 Great Seneca Highway, Rockville, Maryland MD 20850 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Reveragen Biopharma Inc |
| Contact Person: | Eric Hoffman |
| Address: | 9700 Great Seneca Highway, Rockville, Maryland 20850 |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Noncommercial Biotechnical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Reveragen Biopharma Inc was started in 2008 to provide professional Noncommercial Biotechnical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Eric Hoffman for inquiries that concern Reveragen Biopharma Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Reveragen Biopharma Inc can be found at the coordinates 39.096711,-77.203975 as well as the street address 9700 Great Seneca Highway in Rockville, Maryland 20850.
For its online presence, you may visit Reveragen Biopharma Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.